coin-img-SOLSOL+4.66%coin-img-BTCBTC-0.12%coin-img-ETHETH+1.63%coin-img-XRPXRP-2.46%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE+0.81%coin-img-DOGEDOGE+0.46%coin-img-TRXTRX-0.05%coin-img-SOLSOL+4.66%coin-img-BTCBTC-0.12%coin-img-ETHETH+1.63%coin-img-XRPXRP-2.46%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE+0.81%coin-img-DOGEDOGE+0.46%coin-img-TRXTRX-0.05%coin-img-SOLSOL+4.66%coin-img-BTCBTC-0.12%coin-img-ETHETH+1.63%coin-img-XRPXRP-2.46%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE+0.81%coin-img-DOGEDOGE+0.46%coin-img-TRXTRX-0.05%coin-img-SOLSOL+4.66%coin-img-BTCBTC-0.12%coin-img-ETHETH+1.63%coin-img-XRPXRP-2.46%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE+0.81%coin-img-DOGEDOGE+0.46%coin-img-TRXTRX-0.05%

Gland Pharma inks CDMO agreement with annual revenue potential of up to USD 100 million

AI Market Summary
India's Gland Pharma signed a long-term CDMO agreement with an undisclosed global pharmaceutical company to manufacture and supply 55 sterile injectable SKUs across oncology and non-oncology formats. Revenue is expected to begin in 2029, with annualized potential of USD 90–100 million, improving multi-year order visibility but offering limited near-term market impact given the delayed revenue start.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.27%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
India's Gland Pharma has signed a CDMO partnership with an undisclosed global pharmaceutical company to manufacture and supply 55 oncology and non-oncology sterile injectable SKUs. The scope covers multiple formats, including vials, lyophilized products, ampoules and prefilled syringes. The agreement is expected to begin generating revenue in 2029 and carries an annualized revenue potential of USD 90 million to USD 100 million, providing longer-term visibility for the company's business pipeline.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.